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Background: Approximately 10%–15% of people with diabetes develop at least one foot ulcer during their lifetime.
Treatment of diabetic foot ulcers (DFUs) represents a significant economic burden. Enzymatic debridement with
clostridial collagenase ointment (CCO) can be used to remove necrotic tissue from wounds. This study examined the
impact of CCO as an effective adjunct therapy to serial sharp debridement (SSD) and assessed the cost-effectiveness of
CCO compared with standard DFU treatments over 1 year.
Methods: Adults 18 years or older with a diagnosis of type 1 or type 2 diabetes who had a neuropathic DFU were
enrolled in a 12-week, randomized, open-label trial. Patients were randomly assigned to either treatment with
CCO + SSD or to investigator-selected supportive care + SSD (Control). A 3-state Markov model with a 1-week cycle
length was developed using wound-closure rates from the trial to estimate the number of healed-wound weeks and
the expected DFU cost per patient. The 3 states included unhealed, healed, and death. Results were extrapolated to
1 year to estimate the number of healed-wound weeks per treatment and the average cost to achieve epithelialization.
The perspective of the analysis was that of the payer, specifically, the third party payer.
Results: The study sample included 55 patients (28 in CCO group; 27 Control). The majority were men (74.5%) with a
mean age of 57.9 years. Projected healing rates were greater for the CCO + SSD group compared to Control (89% vs.
80%, respectively). The expected number of epithelialized weeks accumulated over 1 year was 25% greater in the
CCO + SSD group than for Control (35 vs. 28 weeks, respectively). Over a 1-year time horizon, the expected cost per
DFU was greater in the Control group than the CCO group ($2,376 vs. $2,099, respectively). The estimated cost per
ulcer-free week was 40% higher for Control ($85/closed-wound week) than for CCO + SSD ($61/closed-wound week).
Conclusions: CCO + SSD therapy is a cost-effective method of debridement in the management of patients with DFUs,
providing better outcomes at a lower cost. Further high quality trials are needed to confirm this finding.
Trial registration: This study was registered at ClinicalTrials.gov as NCT01408277.
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More than 23 million people (approximately 8% of the
population) in the United States (US) currently have dia-
betes mellitus [1]. Among these individuals, approxi-
mately 1%–4% will develop a diabetic foot ulcer (DFU)
annually, and 10%–15% will develop a DFU in their life-
time [2-4]. DFUs are often refractory to therapy and can
be associated with substantial medical complications,
such as osteomyelitis and lower extremity amputation
(LEA). According to systematic literature reviews of
DFUs from 1980 to 2004, between 70,000 and 80,000
patients with diabetes have an amputation every year in
the US [1,5] with resultant escalating comorbidities, add-
itional amputation, and increased risk of mortality [5,6].
The 1-year mortality rate after LEA in people with dia-
betes ranges from 10% to 50%, and the 5-year mortality
rate after LEA is 30%–80% [7-9]. In addition, DFU re-
presents a significant economic burden, accounting for
20%–40% of health resource utilization spent on diabetes
management [3]. The mean annual direct treatment costs
of DFU per patient are approximately $20,000 [10-13],
and costs for treating a DFU 2 years after diagnosis has
increased from $45,301 (in 2008 US dollars) to $49,209 in
2013 [14]. As healthcare costs continue to increase at an
exponential rate, it is important that clinicians understand
the cost-effectiveness of the care that they are administer-
ing so treatments that provide increased clinical benefit
and are considered cost-effective can be utilized [15].
Currently, the 3 major components in treating DFU
are debridement, offloading, and infection control. De-
bridement is generally believed to be a critical factor in
proper wound management [16,17]. Debridement means
“to unleash”. The generally accepted immediate goal of
debridement is the removal of debris and nonviable
tissue as a means to the end goal of unleashing the
capacity of the wound to heal itself. Depending on the
method, debridement may also permit thorough evalu-
ation of wound extent; reduce contamination by patho-
gens and biofilm-forming bacteria; and create a wound
edge composed of cells that have the ability to respond to
molecular signals [18,19]. Serial sharp debridement (SSD)
is generally considered the “gold standard” method for
wound debridement [2,16,17,19]. However, SSD is gener-
ally acknowledged to be a relatively nonselective method
of debriding a wound because normal tissue is also
unavoidably removed. A systematic review of the lit-
erature has concluded that although the rationale for
using SSD to remove devitalized, necrotic tissue and
expose healthier tissue seems logical, the evidence for
its role in enhancing healing is deficient [20]. Several
studies have suggested that SSD may work in synergy
with other treatment approaches, such as growth fac-
tors, cell therapy, or other methods of debridement (i.e.
enzymatic) [16,21-23].Serial or maintenance debridement of DFU is neces-
sary whenever devitalized tissue is present [2,19,24]. Al-
ternative methods of debridement that remove necrotic
tissue while sparing healthy tissue may be advantageous
and decrease the frequency of, or the need for, repeat
SSD. One such approach is enzymatic debridement
using clostridial collagenase ointment (CCO) [25,26]. In
patients with pressure ulcers, CCO as formulated in
Santyl® ointment (Smith & Nephew Inc., Fort Worth,
Texas) has been shown to provide complete and effective
debridement of ulcers in 85% of patients by Day 42 of
treatment without initial or concomitant SSD [27]. CCO
applied daily to a DFU provides ongoing debridement of
the ulcer, and therefore, establishes a wound environment
conducive to healing. In a randomized, parallel-group,
open-label, multicenter, 12-week clinical study comparing
CCO alone and saline-moistened gauze with SSD, only
CCO treatment resulted in a statistically significant mean
percent decrease from baseline in wound area at the end
of treatment and at the end of follow-up (p = 0.01 and
0.01, respectively) [21]. When assessing CCO utilization in
the US, a pharmacoepidemiology analysis of 96 hospital-
based outpatient wound centers revealed that, of 21,677
DFUs treated from 2007–2012, approximately 17% re-
ceived CCO [28].
Only minimal research has been done to assess the
impact of enzymatic debridement as an effective adjunct
therapy to SSD. Given the recent trends in cost contain-
ment for health care systems, it is important for health
care providers and coverage decision makers to compare
the initial cost of advanced therapies to the overall total
cost per episode of care when deciding the appropriate
allocation of resources. Therefore, the objectives of this
study were to assess the cost-effectiveness of CCO




Adults 18 years or older with a diagnosis of type 1 or
type 2 diabetes requiring medications to normalize blood
glucose levels were evaluated for eligibility to participate
in the trial. Eligible participants had to have neuropathic
foot ulcers from 0.5 cm2 to 10 cm2 in area for a minimum
of 30 days. Key eligibility criteria included that participants
have adequate arterial blood flow as evidenced by an ankle
brachial index (ABI) of >0.7 and ≤1.1, be able to follow in-
structions and perform dressing changes at home or have
a caregiver willing to perform dressing changes according
to the protocol, and be willing to use an appropriate off-
loading device when necessary to keep weight off of the
foot ulcer. Alternatively, if ABI was unable to be mea-
sured, a Doppler waveform consistent with adequate
blood flow to the region of the foot with the target ulcer
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able. Patients who had an infection with systemic toxicity;
cellulitis associated with the foot ulcer; lymphangitic
streaking; deep tissue abscess; gangrene; an infection of
the muscle, tendon, joint or bone; foot ulcer tunneling; or
an ulcer on the heel or over a Charcot deformity that
could not be offloaded were excluded from participation
in the trial. The trial was performed in compliance with
the ethical principles of the Declaration of Helsinki and
Good Clinical Practice. The trial protocol and participant
consent forms were reviewed and approved by an accre-
dited Institutional Review Board [Protocol No: 017-101-
09-030, Sterling Institutional Review Board, Atlanta, GA,
USA]; and all participants provided written informed con-
sent before participating in the trial.
Study design and intervention
Clinical findings and methods for this economic analysis
were previously published by Motley et al. [29]. The trial
was a US-based, prospective, randomized, parallel-group,
open-label (non-blinded), multicenter, 12-week clinical
study, carried out at 7 outpatient sites in 5 states (Arizona,
1 site; California, 1 site; Michigan, 1 site; Texas, 3 sites;
and Virginia, 1 site). The trial consisted of a 6-week treat-
ment phase and a 6-week follow-up phase (Figure 1).
Fifty-five study participants were recruited from August
29, 2011 to October 02, 2012. The primary objective of
the trial was to compare the mean percent wound area
change from baseline over the 6-week treatment period,
and at the end of the follow-up period in patients receiv-
ing daily application of CCO (Santyl® ointment) plus sharp
SSD (CCO+ SSD) versus Investigator-selected supportive
care (i.e. silver dressings and hydrogels) plus SSD
(Control). Patients were randomly assigned to either
CCO+ SSD (n = 28) or Control (n = 27) for the 6-week
treatment phase. Treatment was given for 6 weeks and pa-
tients were followed for up to an additional 6 weeks or to
complete wound closure, whichever occurred first. During
the 6-week follow-up phase all ulcers (in both treatment
groups) that had not closed received daily dressing changes
consisting of a foam primary dressing and a single layer
cast padding held in place with a self-adherent bandage.Figure 1 Study schematic. Reproduced with permission from Wounds [29All patients agreed to wear an offloading boot or other ap-
propriate device.
Patients in the CCO+ SSD group had CCO applied
once daily, approximately 2 mm thick, to the foot ulcer.
The wound was gently covered with an Allevyn® nonadhe-
sive dressing (Smith & Nephew, Hull, United Kingdom),
which was maintained in place with a secondary bandage
(Coban®, 3 M, St. Paul, Minnesota). Patients in the Control
group were treated with DFU standard treatments based
on the investigators’ clinical preferences. Investigator-
selected treatment regimens were allowed in order to
emulate ‘real-world’ clinician practice patterns and pre-
ferences. These treatments included wet-to-dry dressings
(n = 5), hydrogel (n = 1), silver dressing (n = 12), silver
sulfadiazine cream (n = 5), or alginate dressing (n = 4), in
addition to SSD. Silvercel® (Systagenix Wound Manage-
ment, Gargrave, United Kingdom) was the primary silver
dressing used by investigators in the clinic and was used
as the reference price (in the cost analysis) for silver dress-
ings. Hyperbaric or negative pressure therapy was not
allowed. At the investigator’s discretion, a hydrogel could
be used if deemed necessary to maintain a moist wound
environment. Wound area was measured at each study
visit using the Applied Research Associated New Zealand
Ltd (ARANZ) Silhouette™ digital image capture and wound
measurement device (ARANZ Medical, Christchurch,
NZ). All patients received SSD commencing with the
Week 1 visit. Patients in both groups received SSD of
the target ulcer at each of the scheduled study visits
(Weeks 2 through 12) if any of the relevant subscales
(Edges, Undermining, Necrotic Tissue Type, or Necrotic
Tissue Amount) of the Wound Assessment Tool were ≥ 3.
If the relevant subscales were all ≤ 2, then SSD was not
performed. The Wound Assessment Tool is a modifica-
tion of the Bates-Jensen tool [30] and provides a standard-
ized, numerical score consisting of 8 subscales in the
assessment of the health and overall condition of the
wound. Although this was an open-label study, allocation
to intervention group was determined using a blinded (or
centralized) randomization sequence to prevent potential
bias resulting from subjectivity in allocation to treatment
(i.e. allocation concealment).].
Figure 2 Three-state diagram of Markov model.
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A Markov model was developed to compare the cost
and outcomes of CCO + SSD versus Control using the
wound closure rates from the clinical trial to estimate
the number of healed wound weeks and the expected
DFU cost per patient. Outputs from the Markov model
were then used to derive a cost-effectiveness ratio for
each treatment group. Using this approach, results were
extrapolated to 1 year to estimate the number of closed-
wound weeks per treatment as well as the average cost
to achieve epithelialization. CCO utilization was derived
based upon the manufacturer’s recommended dosing al-
gorithm [31] using the wound surface area sizes from
the CCO cohort. For this analysis, it was assumed that
wounds were cleaned and dressed daily as they were in
the clinical trial. Over 6 weeks the average CCO
utilization in the clinical trial was 9.5 grams. Because the
clinical trial lasted 12 weeks, 1 tube of CCO was used
in the primary analysis. However, a sensitivity analysis
using 2 tubes was analyzed to assess changes in ex-
pected total costs of care over 1 year. Markov models
are well suited to aid decision-making in clinical situ-
ations when events and costs transition over time
[32]. The Markov model was developed using TreeAge




A 1-year time horizon was chosen to allow sufficient
time for wound closure in both groups. Costs associated
with outpatient treatment continued to accrue until epi-
thelialization was reached.
Three-state markov model and transition probabilities
A 3-state Markov model with a cycle length of 1 week
was chosen to follow the unhealed, healed, and death
stages of a DFU (Figure 2). Since results were extra-
polated out to 1-year, death was included in order to
capture the overall mortality rate of the U.S. population
for individuals 35 years of age and older. State 1, the
unhealed state, represents a healing DFU and, conse-
quently, all the costs associated with treatment in the
outpatient setting (i.e. sharp debridement, enzymatic
debridement, and clinic visits). State 2, the epithelialized
phase, represents a closed wound requiring no further
dressing or treatment and, consequently, incurring no
further costs. State 3, the death state, was defined as a
probability of death (per week) set to 0.000147 on the
basis of Centers for Disease Control data for 2010 annual
mortality rate (all causes) for persons ages 35 and older
(the ages of patients in the clinical trial) [33].
The transition probabilities from the unhealed phase to
the epithelialized phase were determined using wound-closure rates from the clinical trial. At the end of 12 weeks,
approximately 65% of patients in the CCO+ SSD group
were considered healed compared to 47% in the Control
group. These probabilities were extrapolated to 52 weeks
assuming cumulative probability rates over time using
equations described by Briggs et al. [34-36] Additional
file 1: Figure S1]. Using this time-dependent Markov
model provides a robust method to modeling a chronic
illness, since the assumption of constant transition prob-
abilities is considered too restrictive for applications in
healthcare [36]. The probability of ulcer recurrence was
used the Persson et al. model for DFUs [37]. The probabil-
ity of ulcer recurrence from the Persson et al. model was
estimated by a Markov model of diabetic neuropathic
lower extremity ulcers developed by Abt Associates, Inc.
(Abt Inc., Cambridge, MA) [38]. These weekly transition
rates [Table 1] were used to populate the Markov model
and to determine the clinical and economic outcomes.
Weekly transition rates incorporated all daily dressings
and cleanings that occurred throughout the week. Infec-
tion rates were considered for the Markov analysis. Al-
though a few patients who had an infection were admitted
to their local inpatient facilities, the number was small
and was similar between the CCO and Control groups;
therefore, because the hospitalization rates were similar
and would not significantly affect the cumulative costs of
care for either treatment, they were omitted from the
model input.
Clinical outcomes definition
The clinical benefit for the Markov model was defined as
“epithelialized weeks” and represents the expected num-
ber of weeks that the wound was closed over the 1-year
time horizon. This was presented as ulcer-free weeks to
Table 1 Percent of occurrence and transition probabilities
Parameter Percent Weekly transition
probability
CCO + SSD healing rate*
Weeks 1, 6, 9, and 11 5.0 0.05
Weeks 2, 4, and 12 10.0 0.10
Weeks 3, 5, 7, 10, and 19-52 0.0 0.00
Week 8 15.0 0.15
Weeks 13-18 6.9 0.07
Control healing rate*
Weeks 1-2, 4, 6-7, 9, 11, and 26-52 0.0 0.00
Week 3 15.0 0.15
Weeks 5 and 10 5.0 0.05
Weeks 8 and 12 11.0 0.11
Weeks 13-25 5.6 0.06
Ulcer recurrence†
Weeks 1-52 47.1 0.01
All-cause mortality‡ 0.0147 <0.01
CCO, clostridial collagenase ointment; SSD, serial sharp debridement.
*NCT01408277, Briggs et al. [31-33].
†Persson et al. [34].
‡Centers for Disease Control for 2010 for persons 35–95 years [30].
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ing trajectories between the 2 treatment groups. Ulcer-free
weeks represent the average expected time, in weeks, that
DFUs remain closed in the 2 comparative cohorts given
their respective transition probabilities from the unhealed
state to the epithelialized (healed) state. Ulcer-free weeks
are the mathematical complement of open wound weeks
and represent a positive measure of clinical outcome.
Economic outcome definition
The perspective of the analysis was that of the payer, spe-
cifically, the third-party payer. Given that the cost of care
for Medicare beneficiaries with a DFU exceeds $33,000
annually for total reimbursement of all Medicare services
[39], the third-party payer of interest was the Centers
for Medicare and Medicaid Services (CMS). The CMS
maximum-allowable costs were used as proxies for
assessing total cumulative cost of care. Only the direct
medical costs of care were considered in the economic
analysis. All costs were reported in 2013 US dollars, and
no discounting of costs was utilized because the duration
of the model was 1 year. A cost-effectiveness analysis was
performed assessing cost per epithelialized week on a per-
patient basis. Derivation of costs is displayed in Table 2.
Costs for SSD, enzymatic debridement, dressings, wrap-
pings, medications and evaluation and management
(E/M) visits (levels 2 and 3 for physicians and level 2
for facility) were used for the first 12 weeks per the
design of the clinical trial. After 12 weeks, both treatmentarms assumed weekly E/M visits (level 1 for physician and
level 1 for facility). A level 1 E/M visit controls for a
weekly dressing change, assuming the patient did not
achieve complete wound closure. The costs of offloading
were not included in this analysis. CMS does not cover
reimbursement of offloading devices for the treatment of
DFU, except the Total Contact Cast (TCC) [40]. Since
TCC was not used in this trial, costs for offloading devices
were not included in the economic model as they are a
direct cost to the patient.
Sensitivity analyses
All sensitivity analyses were performed in TreeAge Pro
(TreeAge Pro version 2013, TreeAge Software Inc.,
Williamstown, Massachusetts). Sensitivity analysis is the
process of changing the value of an input parameter to
assess the magnitude of its effect on the final results of
the analysis. This type of analysis tests the robustness of
the models assumptions (i.e. variables chosen for model
input) on the results. Deterministic sensitivity analysis
provides an explanation for the source of ranges used,
along with justification for choice of the variables in-
cluded. In this analysis, the probability of healing for
CCO and Control; the costs of SSD, enzymatic debride-
ment and clinic visits; and the probability of ulcer recur-
rence were included in the sensitivity analyses. Clinical
trials invariably include wounds with a large variety of
sizes and shapes. Given the uncertainty that exists in
rates of healing with wounds of various sizes and shapes
[41], a ±50% compared with the base case was utilized
to increase the robustness of the model’s results. In
addition, the frequency of dressing changes was varied
from twice daily to once every 3 days; and the amount
of CCO utilization was varied from 1 to 2 tubes. Outputs
were displayed in a tornado diagram for one-way analyses.
A tornado diagram graphically depicts changes in results
relative to changes in model input assumptions and ranks
these changes according to their magnitude. Variables
with substantial uncertainty or expectation of sensitivity
were selected for these analyses.
A probabilistic sensitivity analysis was performed to
evaluate parameter uncertainty by using second-order
Monte-Carlo simulations of 10,000 trials in which all
model inputs were varied simultaneously. This method
is comprised of generating a “dummy” data set by resam-
pling with replacement (i.e. randomly selecting 1 patient
at a time) from the original data set and repeating this
random patient selection until the dummy data set
reaches the same size as the original [32].
Results
A total of 55 participants were included in this study.
Participant’ and wound characteristics are displayed in
Table 3. The majority of the participants were men
Table 2 Unit cost table
Category Item Current procedural terminology/
diagnosis-related group code
Medicare costs
Clinic visits*† Physician, SSD 97597 $23.48
Facility, SSD 97597 $106.96
Facility, enzymatic debridement 97602 $71.54
Physician, clinic visit (level 1) 99211 $8.85
Facility, clinic visit (level 1) 99211 $56.77
Physician, clinic visit (level 2) 99212 $24.50
Facility, clinic visit (level 2) 99212 $73.68
Physician, clinic visit (level 3) 99213 $49.67
Dressings‡ Silvercel A6196§ $7.96 each
Alginate A6196§ $7.96 each
Allevyn® nonadhesive A6209§ $8.09 each
Hydrogel sheeting dressing A6242§ $7.17 each
Wet-to-dry gauze A6402§ $0.13 per yard
4x4 gauze A6402§ $0.13 per yard
Wrappings¶ Coban® A6454§ $0.84 per yard
Coflex A6454§ $0.84 per yard
Medication Collagenase ointment (CCO) J3590§ $182.76 per tube
Silver sulfadiazine 1% cream 591081055‖ $9.94 per tube
CCO, clostridial collagenase ointment; DFU, diabetic foot ulcer; SSD, serial sharp debridement.
*”Clinic” refers to a hospital-based outpatient wound care department.
†If any type of debridement occurred, then no clinic visit billing was allowed. If there was no debridement, the clinic visit codes were used because dressings
were changed frequently. When enzymatic debridement was performed, only the facility was reimbursed.
‡Only Allevyn® non-adhesive was used in patients who received CCO. Other dressings were considered standard of care in the treatment of DFU.
§Healthcare Common Procedure Coding System code.
¶Each dressing was wrapped after applying CCO or standard-of-care dressing.
‖National drug code.
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(standard deviation [SD] = 12.3). Nearly all of the partici-
pants were under 85 years (94.5%), White/Caucasian
(85.5%) and non-Hispanic/Latino (83.6%). The average
wound surface area was 1.9 cm2 (SD = 1.4), and the
mean ankle brachial index was 1.0 (SD = 0.1). The ma-
jority of wounds were plantar (78.2%) or plantar/medial
(10.9%) and located on the left foot (56.4%). For the
6-week treatment phase, the average number of SSDs
was 4.1 (SD = 1.8), and decreased during the 6-week
follow-up phase (3.1, SD = 2.3). Wounds treated with
CCO + SSD decreased in area from an average of
1.9 cm2 at baseline to 0.6 cm2 at the end of the treat-
ment phase (p < 0.001). Wounds in the Control group
went from an average area of 1.8 cm2 to 1.2 cm2, which
was not statistically significant (p = 0.31). At the end of
the follow-up phase, average wound area was 0.8 cm2
in the CCO + SSD group (p < 0.001 from baseline) and
1.2 cm2 in the Control group.
Expected wound closure rates between CCO + SSD
and Control are displayed in Figure 3. Controlling for
death rates and ulcer recurrence over 1 year, the projected
healing rates were greater for the CCO + SSD group(89% vs. 80%, respectively). The primary clinical out-
come for this economic analysis was closed-wound weeks.
On the basis of the transition rates of the prospective
clinical trial data previously published by Motley et al.
[29], the expected number of epithelialized weeks accu-
mulated over 1 year was 25% greater in the CCO+ SSD
group compared with the Control group (35 vs. 28 weeks,
respectively; Figure 4). To provide another perspec-
tive, the clinical compliment to epithelialized weeks (i.e.
closed-wound weeks) is open-wound weeks. Conse-
quently, the number of expected open-wound weeks
for the CCO + SSD and Control cohorts is estimated
at 17 and 24 weeks, respectively. That is, patients re-
ceiving the Control intervention would have, on aver-
age, 7 additional open-wound weeks (approximately 2
extra months) compared with patients treated with en-
zymatic debridement as an adjunct to SSD.
A 1-year time span was selected to adequately model
the total costs across the entire episode of care for both
treatment groups. One year was selected in order to cap-
ture the additional costs of closure that occur past the
12 weeks of the study. However, it should be noted that
during the 12-week clinical trial, CCO had higher rates
Table 3 Patient demographics and wound characteristics
Total CCO Control p-value
Demographic (n = 55) (n = 28) (n = 27) ANOVA/Chi-square
Age
Mean ± SD 57.9 ± 12.3 56.9 ± 12.0 59.0 ± 12.7 0.54
Minimum, Maximum 35.0, 97.0 35.0, 97.0 39.0, 88.0
Geriatric, n (%)
<85 years 52 (94.5) 27 (96.4) 25 (92.6) 0.53
≥85 years 3 (5.5) 1 (3.6) 2 (7.4)
Sex, n (%)
Men 41 (74.5) 21 (75.0) 20 (74.1) 0.94
Women 14 (25.5) 7 (25.0) 7 (25.9)
Race, n (%)
White/Caucasian 47 (85.5) 25 (89.3) 22 (81.5) 0.41
Black/African American 8 (14.5) 3 (10.7) 5 (18.5)
Ethnicity, n (%)
Hispanic/Latino 9 (16.4) 5 (17.9) 4 (14.8) 0.76
Non-Hispanic/Latino 46 (83.6) 23 (82.1) 23 (85.2)
Ankle brachial index, n (%)
n* 33 (60.0%) 16 (57.1) 17 (63.0) 0.52
Mean ± SD 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1
Minimum, Maximum 0.8, 1.1 0.8, 1.1 0.8, 1.1
Wound area (cm2)
Mean ± SD 1.9 ± 1.4 2.0 ± 1.1 1.8 ± 1.6 0.73
Minimum, Maximum 0.1, 7.5 0.1, 4.6 0.2, 7.5
Wound location, n (%)
Distal 2 (3.6) 1 (3.6) 1 (3.7) 0.38
Lateral 3 (5.5) 2 (7.1) 1 (3.7)
Lateral/dorsal/distal 1 (1.8) 0 (0.0) 1 (3.7)
Plantar 43 (78.2) 20 (71.4) 23 (85.2)
Plantar/medial 6 (10.9) 5 (17.9) 1 (3.7)
Wound side, n (%)
Left foot 31 (56.4) 14 (50.0) 17 (63.0) 0.33
Right foot 24 (43.6) 14 (50.0) 10 (37.0)
Number of sharp debridements
6 Treatment weeks
Mean ± SD 4.05 ± 1.83 4.07 ± 1.88 4.04 ± 1.81 0.45
Minimum, Maximum 1.0, 6.0 1.0, 6.0 1.0, 6.0
6 Follow-up treatments
N 39 (70.9%) 20 (71.4%) 19 (70.4%)
Mean ± SD 3.11 ± 2.32 3.32 ± 2.24 2.89 ± 2.45 0.81
Minimum, Maximum 0.0, 6.0 0.0, 6.0 0.0, 6.0
ANOVA, analysis of variance; CCO, clostridial collagenase ointment; SD, standard deviation.
*Not all patients had an ankle brachial index assessment.
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cost compared with Control. The differences in the epi-
thelialization rates between CCO and Control as anadjunct to SSD led to differences in cost between the 2
therapies. Once the DFU epithelializes, wound care ther-





























Figure 3 Expected wound closure rates for CCO + SSD and control treatments. CCO, clostridial collagenase ointment; SSD, serial sharp
debridement.
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the expected costs per DFU at the end of the study (i.e.,
12 weeks) were $1,580 and $1,530 for the CCO + SSD
and Control groups, respectively. However, given the
difference in the wound closure trajectories between
CCO + SSD and Control, the expected cost (2013 US
dollars) per DFU over a 1-year time horizon was $2,099
in the CCO + SSD group and $2,376 in the Control
group, a difference of $277 (Figure 5). When CCO utili-
zation was increased to 2 tubes, the expected cost of care
over 1-year rose by only $66 (from $2,099 to $2,165), still
providing a cost savings of $211 compared with the cost
in the Control group.
When the total costs of DFU care were estimated over
the course of 1-year, CCO + SSD therapy provided better
clinical outcomes at a lower cost of care relative to Con-
trol therapy. Patients treated with Control incurred total























Figure 4 Healed wound weeks among patients treated with CCO + S
sharp debridement.than those receiving CCO + SSD. The clinical benefit of
CCO + SSD was approximately 25% greater than for
Control. The estimated cost per ulcer-free week was
40% higher for Control ($85/closed-wound week) than
for CCO + SSD ($61/closed-wound week).
Sensitivity analyses
One-way sensitivity and probabilistic sensitivity analyses
were performed on the Markov model parameters to de-
termine the effects of uncertainty on the model assump-
tions. All model parameters were varied by ±50%, with the
exception of the frequency of dressing changes, which
were varied from twice daily to once every 3 days. The
one-way deterministic sensitivity analyses revealed no
thresholds where CCO+ SSD lost economic dominance.
The tornado diagram shows which variables exerted the
most influence on outcomes (Additional file 2: Figure S2).


















Figure 5 Cumulative costs for CCO + SSD and control treatments. CCO, clostridial collagenase ointment; SSD, serial sharp debridement.
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of the largest varying costs in DFU therapy is the cost/fre-
quency of dressing changes. The assumption is that the
clinical outcomes remain the same with costs varying
because of the frequency of dressing changes. Rates of
healing for patients treated with CCO+ SSD and ulcer
recurrence also exerted influence on outcomes. CCO uti-
lization had no substantial influence on outcomes. Results
from the probabilistic sensitivity analysis (i.e., Monte Carlo
Simulation) indicated that costs for CCO+ SSD were
lower compared with Control. CCO + SSD had the highest
average effectiveness of 35 ulcer-free weeks (SD = 1), while
the Control group had fewer ulcer-free weeks (28 weeks,
SD = 2) (Additional file 3: Table S1).
Discussion
DFUs often require substantial healing time and are
associated with increased risk for infections and other
events that can result in severe and costly outcomes
[42]. The economic burden of DFU can be explained by
multiple factors, including late management of diabetes,
high recurrence and amputation rates, complexity of treat-
ment modalities on patients with osteomyelitis, and high
morbidity and mortality rates after amputation [43]. The
results of this Markov analysis demonstrate that, although
CCO is more expensive compared with pharmacoloigcally
inert dressings used in the Control group, enzymatic de-
bridement with CCO as an adjunct to SSD can accelerate
wound closure, thus reducing the overall cost of DFU
care. Findings from the current investigation indicate how
the addition of CCO to DFU treatment can reduce
the total direct cost of DFU care to the payer. Al-
though the cost of a 30-gram tube of CCO was almost 3
times the cost of Control dressings, the therapeutic effect
of CCO+ SSD was approximately 25% greater than for
Control when wound closure was measured across
the entire episode of care.Annual healthcare costs associated with chronic
wound treatment in the U.S. approaches $33 billion
[44,45]. Overall, the U.S. spends twice as much per capita
as the United Kingdom, Sweden and the Netherlands, yet
these countries achieve better overall health outcomes
[46]. In 2006 the Tax Relief and Health Care Act was
passed, which authorized the establishment of a pay-for-
performance program known as Physician Quality Report-
ing Initiative wherein payment is linked to whether the
clinician performs certain tasks in a given time frame for
specific patients [47]. Currently there is a Physician Quality
Reporting Initiative measure relating to diabetic “foot care”,
specifically, performing peripheral neuropathy evalu-
ation and prescribing appropriate footwear [47]. How-
ever, offloading of an existing DFU is not a Physician
Quality Reporting Initiative measure. As the population
ages and the prevalence of diabetes and obesity increase
it will be important for third-party payers, such as
Medicare and Medicaid, to evaluate the efficacy and ef-
fectiveness of treatment practice patterns and Physician
Quality Reporting Initiative measures in wound care.
Treatment with CCO+ SSD provided 35 ulcer-free
weeks compared with 28 weeks in the Control cohort.
Stated differently, CCO + SSD had an average expected
time to closure of 17 weeks compared with 24 weeks in
the Control cohort. These 7 additional open-wound weeks
can have substantial clinical, economic, and humanistic
impact. The longer a wound remains unhealed, the greater
the risk for infection, decreased health-related quality of
life, and higher cost of care. Infection control is of ut-
most importance in DFU treatment because infection is
strongly associated with amputation. Lavery et al. pro-
spectively determined risk factors for infection and
found that wounds that penetrated the bone had a
greater than 30 day duration and a traumatic etiology,
were recurrent, occurred in patients with peripheral vas-
cular disease, and had a significantly higher increased risk
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2 months earlier using CCO as an adjunct to SSD
could help reduce downstream implications and costs
of care for DFU. In addition, the overall cost of care for
the CCO + SSD cohort yielded a cost savings of $277
(US dollars) compared with Control. These results dem-
onstrate the economic value of CCO for the treatment of
DFUs in outpatient settings.
Per the inclusion/exclusion criteria of this study, the
majority of wounds fell into a specific size range; that is,
wound area was ≥ 0.1 cm2 and ≤ 7.5 cm2. In a large
retrospective study of 26,599 diabetic wounds, 60% had
a mean wound area of > 0.5 cm2 and < 7 cm2 [49]; there-
fore, ulcer size in this study is applicable to other DFU
patient populations. Regarding age, sex, and race/ethni-
city, patients in this study are generalizable to the overall
DFU population [50,51].
A limited number of economic analyses comparing
advanced therapies with other standards of care exist
(particularly within DFU patient populations) [21,52-55];
and results of these analyses are consistent with the
current study’s clinical and cost-effectiveness findings.
Tallis et al. found that CCO therapy resulted in a higher
likelihood of wound surface area reduction, significantly
better response rates compared with standard of care
DFU therapy, and lower direct average costs per re-
sponder in the hospital outpatient department setting
over 12 weeks compared with saline-moistened gauze/
SSD ($1,607 versus $1,980 US dollars, respectively) among
patients with DFUs [21]. Another study by Waycaster
et al. using randomized clinical trial data from a long-term
care setting showed that CCO had fewer expected wound
days (48 versus 147, respectively) at substantially lower
cost ($2,003 versus $5,480, respectively) compared with
autolytic debridement using a hydrogel dressing for
the treatment of pressure ulcers over a 1-year time
period [55].
Certain limitations should be considered when inter-
preting our findings. First, the clinical data used in this
analysis were derived from a clinical trial conducted in 7
outpatient sites in 5 states with a relatively small patient
sample (55 patients); therefore, the results cannot ne-
cessarily be generalized to other dressings, health care
settings, or to wounds of other etiologies. Second, this
investigation was unblinded, so ascertainment bias can-
not be ruled out. However, an open-label (non-blinded)
trial was chosen intentionally to allow clinically relevant
standard care in the control group, with allocation bias
and assessment bias controlled through appropriate
randomization and allocation concealment, and the use
of a wound measurement device (ARANZ). Third, inves-
tigators were only permitted to conduct a SSD if one or
more of the subscale parameters of Edges, Undermining,
Necrotic Tissue Type, or Necrotic Tissue Amount of theWound Assessment Tool was ≥ 3. This requirement did
not allow for an independent assessment of the relative
frequency of SSD for CCO versus Control, as similarity
in wound assessment scores necessarily resulted in simi-
larity in use of SSD. Nevertheless, because the frequency
of SSD was essentially the same between the 2 treatment
groups, the frequency of debridement may be treated as
a constant, and therefore, the different outcomes for the
2 groups can be ascribed to the actual treatments used
(ie, CCO or the various Control regimens). However,
after consultation with wound care specialists, debride-
ment would be conducted in those situations (i.e. under-
mining, predominance of fibrous or necrotic tissue).
Therefore, although debridement was protocol-driven in
this study, it is not expected that clinicians would de-
bride differently in a clinical setting. Results indicate that
SSD used in conjunction with CCO provides faster heal-
ing than SSD used with passive supportive therapies.Conclusions
The results of this study demonstrate that CCO is a
cost-effective adjunct therapy to SSD. DFUs treated with
CCO + SSD yielded almost 2 extra ulcer-free months
while costing approximately $300 less than Control. In
addition, DFU patients treated with CCO + SSD showed
an enhanced rate of healing during the treatment period,
and in the follow-up period when cessation of treatment
occurred compared to Control.
Enzymatic debridement of DFU with CCO as an
adjunct to SSD offers better value compared with various
commonly used nonenzymatic supportive care regardless
of the outpatient care setting. CCO + SSD therapy is a
cost-effective method of debridement in the management
of patients with DFU, providing better outcomes at a
lower cost of care. Health care providers should consider
CCO when using SSD in the treatment of DFUs, although
further high quality trials are required to confirm our
findings.Additional files
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